Brind.

Steve Cohen recommended Zai Lab as a biotech stock, and Leerink partners raised the price target for Zai Lab on July 25, 2025.

1 report, 1 independent Updated Jul 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Steve Cohen Leerink partners

Keep exploring

The entities involved

Steve Cohen
researcher (ORCID 0000-0002-9471-4586)

Nothing else this week.
Leerink partners
U.S. investment bank
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38

Coverage

Newest first; wire copies grouped

Jul 25Insider MonkeyZai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment Zai Lab Ltd (NASDAQ:ZLAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On June 30